[go: up one dir, main page]

Latest News for: iib

Edit

Cereno Scientific Completes All Dosing and Participant Visits in CS014's FDA-Aligned PK-Bridging Study, Advancing Capital-Efficient Path Toward Phase IIb in PH-ILD (Cereno Scientific AB)

Public Technologies 07 Jul 2026
2026-07-07 11.00.00 CEST Cereno Scientific AB - Investor News Cereno Scientific Completes All Dosing and Participant Visits in CS014's FDA-Aligned PK-Bridging Study, Advancing Capital-Efficient Path Toward Phase IIb in PH-ILD.
Edit

TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a

Caledonian Record 29 Jun 2026
All 63 donor-recipient pairs enrolled and treated according to ...
Edit

TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New ...

Nasdaq Globe Newswire 29 Jun 2026
Clinical Phase II milestone. All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers ... .
Edit

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic ...

Morgan Citizen 29 Jun 2026
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ... .
Edit

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone (Form 8-K) (Regenxbio Inc)

Public Technologies 29 Jun 2026
RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
Edit

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

PR Newswire 29 Jun 2026
RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
Edit

Sibel Health Receives EU MDR Class IIb CE Mark for ANNE® One: The First Wireless ...

The Columbus Telegram 11 Jun 2026
Class IIb certification and SDC interoperability bring traditional patient-monitor to a wireless, wearable form factor ... .
Edit

DermaSensor gibt die CE-Kennzeichnung der Klasse IIb sowie die Zusammenarbeit mit dem NHS bekannt und ...

The Joplin Globe 11 Jun 2026
MIAMI--(BUSINESS WIRE)--Jun 11, 2026-- ... .
Edit

DermaSensor Announces Class IIb CE Mark and Collaboration with NHS, Marking the Beginning of Its ...

Enid News & Eagle 10 Jun 2026
MIAMI--(BUSINESS WIRE)--Jun 10, 2026-- ... .
Edit

Sibel Health Receives EU MDR Class IIb CE Mark for ANNE® One: The First Wireless Wearable Patient Monitoring Platform Certified to Key Interoperability Standards

PR Newswire 10 Jun 2026
Class IIb certification and SDC interoperability bring traditional patient-monitor to a wireless, wearable form factor ... Union Medical Device Regulation (EU MDR 2017/745) as a Class IIb medical device.
Edit

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

Nasdaq Globe Newswire 05 Jun 2026
The study showed that orelabrutinib was safe and well tolerated in participants with SLE ... .
Edit

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

PR Newswire 04 Jun 2026
Early outcomes from the PROCEED phase IIb trial of bocunebart (Lu AG09222) ... The Phase IIb trial was designed to establish the optimal dose and route of administration (subcutaneous and intravenous) of bocunebart.
Edit

Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA ...

Auburnpub dot com 30 May 2026
... from the Phase IIb ENLIGHT study of Efsubaglutide alfa .
Edit

Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions

PR Newswire 29 May 2026
Phase IIb ENLIGHT Study ... Innogen's proprietary Efsubaglutide α met the primary endpoint of the Phase IIb ENLIGHT study conducted in Chinese overweight and obese adults ... The Phase IIb clinical trial ...
Edit

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Nasdaq Globe Newswire 23 Apr 2026
Dosing initiates clinical evaluation of NPX-5, a ...

Article Search

tools
×
×
×
×